Article Text

Download PDFPDF

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.
  1. D H Miller,
  2. F Barkhof,
  3. I Berry,
  4. L Kappos,
  5. G Scotti,
  6. A J Thompson
  1. University Department of Clinical Neurology, Institute of Neurology, London, UK.


    Serial gadolinium enhanced MRI of the brain detects much clinically silent disease activity in early relapsing-remitting and secondary progressive multiple sclerosis (MS), and thus has an important role in monitoring the effects of therapy. Based on the proceedings of a recent Commission of the European Communities (CEC) workshop and a review of the literature, guidelines are presented for using MRI to monitor treatment trials in MS. The guidelines consider: A) MRI system and techniques; B) patient selection; C) trial design; D) analysis of results. Priorities for future research are also indicated.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles